Related Experiment Video

Updated: Mar 15, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.5K

Toll-like receptors targeting technology for the treatment of lymphoma

Maria Batool1, Muhammad Ayaz Anwar1, Sangdun Choi1

  • 1a Department of Molecular Science and Technology , Ajou University , Suwon , Korea.

Expert Opinion on Drug Discovery
|September 8, 2016
PubMed
Abstract

Insights

Toll-like Receptors (TLRs) play a dual role in lymphoma, potentially hindering or aiding treatment. Modulating TLRs offers a promising strategy for lymphoma regression and improved therapeutic outcomes.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Toll-like Receptors (TLRs) are key in innate and adaptive immunity.
  • TLRs exhibit a dual role in cancer, influencing tumor growth promotion or suppression.
  • Lymphomas are cancers of the lymphatic system and blood cells where TLRs have a significant impact.

Purpose of the Study:

  • To explore the potential role of Toll-like Receptors (TLRs) in the context of lymphomas.
  • To discuss the dual function of TLRs in either exacerbating lymphoma or improving treatment efficacy.
  • To highlight the desirability of utilizing TLRs for immune modulation to achieve lymphoma regression.

Main Methods:

  • Literature review on the role of TLRs in innate and adaptive immunity.
  • Analysis of TLRs' function in various cancer types, with a focus on lymphomas.
  • Exploration of current and novel strategies for TLR-mediated lymphoma treatment.

Main Results:

  • TLRs act as inflammation-inducing receptors with a significant impact on lymphoma progression and treatment.
  • Modulating the immune system via TLRs presents a desirable therapeutic avenue for lymphoma regression.
  • Existing strategies using TLR ligands have shown success, but further optimization is needed.

Conclusions:

  • TLRs are critical regulators in lymphoma, offering potential for therapeutic intervention.
  • Fine-tuning TLRs is essential for optimizing lymphoma treatment strategies.
  • Novel ligands, improved pharmacodynamics, and targeted delivery systems are crucial for enhancing TLR-based lymphoma therapies.
Keywords:
B-cell receptorToll-like receptorcancer therapyligandlymphoma

More Related Videos

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

1.1K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K